CRMD News & Events

Ahead of the company's upcoming investor conference presentations next week, CorMedix also maintains its FY27 DefenCath sales outlook of $150M-$170M.

Reports Q4 revenue $128.615M, consensus $127.02M. Joe Todisco, CorMedix Chairman and CEO, commented, "I am proud of the Company's progress over the past year as we have accelerated the expansion of patient access for DefenCath, completed our acquisition and integration of Melinta, and saw progress in our two ongoing Phase 3 clinical programs for Rezzayo prophylaxis and DefenCath in TPN. With the announcement of our share repurchase program and multiple near-term milestones on the horizon, most notably the Rezzayo ReSPECT phase III data, CorMedix is focused on driving business growth and shareholder value over the year ahead."

CorMedix Therapeutics announced its Board of Directors has approved a share repurchase program, which authorizes the Company to repurchase up to $75 million of the Company's outstanding common stock. The repurchase program is authorized through December 31, 2027. CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately $150 million in cash and cash equivalents, and 79.3 million common shares outstanding as of December 31, 2025.